Related Experiment Video
Updated: Mar 8, 2026

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
[Clinical characteristics of clonal evolution after immunosuppressive therapy in children with severe/very severe
Jing-Liao Zhang1, Tian-Feng Liu, Li-Xian Chang
1Department of Pediatric Blood Diseases, Institute of Hematology & Blood Disease Hospotial, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China. xfzhu@ihcams.ac.cn.
Insights
Children with severe/very severe aplastic anemia (SAA/VSAA) receiving immunosuppressive therapy (IST) face risks of clonal evolution. High CD3+ T cell percentage or lack of IST response predict unfavorable progressions, impacting survival outcomes.
Area of Science:
- Hematology
- Pediatric Oncology
- Immunosuppression Therapy
Background:
- Severe/very severe aplastic anemia (SAA/VSAA) is a life-threatening condition.
- Immunosuppressive therapy (IST) is a standard treatment for SAA/VSAA.
- Clonal evolution can occur after IST, leading to adverse outcomes.
Purpose of the Study:
- To investigate the clinical characteristics of clonal evolution after IST in pediatric SAA/VSAA.
- To identify risk factors associated with unfavorable clonal evolution post-IST.
Main Methods:
- Retrospective analysis of clinical data from 231 children with newly-diagnosed SAA/VSAA treated with IST.
- Evaluation of the incidence and risk factors for clonal evolution, including cytogenetic abnormalities and paroxysmal nocturnal hemoglobinuria (PNH) clones.
- Univariate and Cox multivariate analyses to determine independent risk factors for unfavorable progressions.
Main Results:
- The 5-year overall survival rate was 82.7%.
- Fifteen patients experienced clonal evolution post-IST, with 5 favorable (PNH and trisomy 8) and 10 unfavorable (monosomy 7, MDS/AML) progressions.
- Independent risk factors for unfavorable progressions included elevated CD3+ T cell percentage (>80%) and lack of response to IST.
Conclusions:
- Children with SAA/VSAA and a high CD3+ T cell percentage at diagnosis are at increased risk of unfavorable progressions.
- Lack of response to IST is a significant predictor of adverse outcomes in pediatric SAA/VSAA patients.
Objective:
To evaluate the clinical characteristics and risk factors of clonal evolution after immunosuppressive therapy (IST) in children with severe/very severe aplastic anemia (SAA/VSAA).
Methods:
The clinical data of 231 children with newly-diagnosed SAA/VSAA who received IST were retrospectively studied. The incidence and risk factors of clonal evolution after IST were analyzed.
Results:
The 5-year overall survival rate of the 231 patients was 82.7%. Except for 18 cases of early deaths, 213 patients were evaluated for IST efficacy. Among the 231 patients, cytogenetic abnormalities for at least two chromosome metaphase were detectable in 14 (7.4%) patients, and PNH clones were detectable in either peripheral red blood cells or neutrophils for 95 patients. Among the 213 patients evaluated for IST efficacy, 15 patients experienced clonal evolution after IST. Five patients had PNH and trisomy 8 which were defined as favorable progressions, and ten patients experienced monosomy 7 and MDS/AML as unfavorable progressions. The 5-year accumulative incidence of favorable and unfavorable progression were (2.2±2.2)% and (4.8±3.3)%, respectively. Until the last follow-up, 100% (5/5) of patients with favorable progressions and 50% (5/10) of patients with unfavorable progressions survived. WBC>3.5×109/L, CD3+T cell percentage>80%, dosage of antithymocyte globulin >3.0 mg/(kg·d) and no response to IST were related to unfavorable progressions by univariate analysis. Cox multivariate analysis revealed that an increased CD3+T cell percentage (>80%) and no response to IST were independent risk factors for unfavorable progressions.
Conclusions:
The children with SAA/VSAA who have an increased CD3+T cell percentage at diagnosis or have no response to IST are in high risks of unfavorable progressions.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Cells of the Adaptive Immune Response
Differentiation of Common Myeloid Progenitor Cells
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

